252 related articles for article (PubMed ID: 18670647)
1. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.
Liu W; Xie CC; Zhu Y; Li T; Sun J; Cheng Y; Ewing CM; Dalrymple S; Turner AR; Sun J; Isaacs JT; Chang BL; Zheng SL; Isaacs WB; Xu J
Neoplasia; 2008 Aug; 10(8):897-907. PubMed ID: 18670647
[TBL] [Abstract][Full Text] [Related]
2. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.
Kloth JN; Oosting J; van Wezel T; Szuhai K; Knijnenburg J; Gorter A; Kenter GG; Fleuren GJ; Jordanova ES
BMC Genomics; 2007 Feb; 8():53. PubMed ID: 17311676
[TBL] [Abstract][Full Text] [Related]
3. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.
Kim YH; Girard L; Giacomini CP; Wang P; Hernandez-Boussard T; Tibshirani R; Minna JD; Pollack JR
Oncogene; 2006 Jan; 25(1):130-8. PubMed ID: 16116477
[TBL] [Abstract][Full Text] [Related]
4. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
[TBL] [Abstract][Full Text] [Related]
5. Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer.
Savinainen KJ; Linja MJ; Saramäki OR; Tammela TL; Chang GT; Brinkmann AO; Visakorpi T
Br J Cancer; 2004 Mar; 90(5):1041-6. PubMed ID: 14997205
[TBL] [Abstract][Full Text] [Related]
6. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study.
Cheng Y; Liu W; Kim ST; Sun J; Lu L; Sun J; Zheng SL; Isaacs WB; Xu J
Cancer Genet; 2011 Jul; 204(7):375-81. PubMed ID: 21872824
[TBL] [Abstract][Full Text] [Related]
8. DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma.
Armengol G; Knuutila S; Lluís F; Capellà G; Miró R; Caballín MR
Cancer Genet Cytogenet; 2000 Jan; 116(2):133-41. PubMed ID: 10640145
[TBL] [Abstract][Full Text] [Related]
9. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer.
Reiter RE; Sato I; Thomas G; Qian J; Gu Z; Watabe T; Loda M; Jenkins RB
Genes Chromosomes Cancer; 2000 Jan; 27(1):95-103. PubMed ID: 10564591
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X; Porter AT; Honn KV
Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
[TBL] [Abstract][Full Text] [Related]
11. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.
Beà S; Salaverria I; Armengol L; Pinyol M; Fernández V; Hartmann EM; Jares P; Amador V; Hernández L; Navarro A; Ott G; Rosenwald A; Estivill X; Campo E
Blood; 2009 Mar; 113(13):3059-69. PubMed ID: 18984860
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.
Lai J; Flanagan J; Phillips WA; Chenevix-Trench G; Arnold J
Br J Cancer; 2003 Jan; 88(2):270-6. PubMed ID: 12610513
[TBL] [Abstract][Full Text] [Related]
13. Distinct Genomic Alterations in Prostate Tumors Derived from African American Men.
Liu W; Zheng SL; Na R; Wei L; Sun J; Gallagher J; Wei J; Resurreccion WK; Ernst S; Sfanos KS; Isaacs WB; Xu J
Mol Cancer Res; 2020 Dec; 18(12):1815-1824. PubMed ID: 33115829
[TBL] [Abstract][Full Text] [Related]
14. High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer.
van Duin M; van Marion R; Vissers K; Watson JE; van Weerden WM; Schröder FH; Hop WC; van der Kwast TH; Collins C; van Dekken H
Genes Chromosomes Cancer; 2005 Dec; 44(4):438-49. PubMed ID: 16130124
[TBL] [Abstract][Full Text] [Related]
15. RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer.
Porkka KP; Tammela TL; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2004 Jan; 39(1):1-10. PubMed ID: 14603436
[TBL] [Abstract][Full Text] [Related]
16. Computational method for estimating DNA copy numbers in normal samples, cancer cell lines, and solid tumors using array comparative genomic hybridization.
Abkevich V; Iliev D; Timms KM; Tran T; Skolnick M; Lanchbury JS; Gutin A
J Biomed Biotechnol; 2010; 2010():. PubMed ID: 20706610
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide analysis of recurrent copy-number alterations and copy-neutral loss of heterozygosity in head and neck squamous cell carcinoma.
Marescalco MS; Capizzi C; Condorelli DF; Barresi V
J Oral Pathol Med; 2014 Jan; 43(1):20-7. PubMed ID: 23750501
[TBL] [Abstract][Full Text] [Related]
18. Detailed genomic mapping and expression analyses of 12p amplifications in pancreatic carcinomas reveal a 3.5-Mb target region for amplification.
Heidenblad M; Jonson T; Mahlamäki EH; Gorunova L; Karhu R; Johansson B; Höglund M
Genes Chromosomes Cancer; 2002 Jun; 34(2):211-23. PubMed ID: 11979555
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.
Heidenblad M; Schoenmakers EF; Jonson T; Gorunova L; Veltman JA; van Kessel AG; Höglund M
Cancer Res; 2004 May; 64(9):3052-9. PubMed ID: 15126341
[TBL] [Abstract][Full Text] [Related]
20. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
